Glenmark Pharmaceuticals has informed that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at the Company’s formulation manufacturing facility based out of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9th September to 20th September, 2024. The inspection closed with no observation.
The above information is a part of company’s filings submitted to BSE.